Houston software entrepreneur discusses company growth and the importance of remembrance during Pride Month

Featured Innovator

For Cody Gremminger, this month is about remembrance. Courtesy of Cyber One Solutions

One day, Cody Gremminger sat down with his fiance, Brian Carrico, and decided going into business together was something they wanted to explore. They put their heads together, thought of a name — Cyber One Solutions — and created a management, service and IT support company that serves the greater Houston area with satellite offices in Austin, Dallas, Lufkin, Brenham, and Beaumont.

Cyber One Solutions has experienced massive growth in less than two years of being in business, and InnovationMap sat down to talk with Gremminger about Cyber One's next steps, what it's like working with your partner, and the importance of the support gained by the LGBTQ community.

InnovationMap: Your company is less than two years old, but you’ve had massive growth and success. What are some lessons that you’ve learned throughout that time?

Cody Gremminger: We're an IT company, so definitely making sure that we have a huge book of processes and everything like that. Organization is one of the most important things. Finding good people that treat your clients that way that you treat them. Whenever you start off with a company and it's just the two founders, you know how you want to treat all of your clients. But it is hard to find people to treat the clients the same way you want to treat them.

IM: What do the next steps of Cyber One Solutions look like?

CG: The next steps of the company at this point are to keep growing and keep taking care of our current clients, just like every company in their infancy age.

IM: Are you planning on growing your team or slate of services anytime soon?

CG: We are looking into both. We have a couple of our team members working on getting further certifications and further training into new aspects of IT. We're also working on growing our current client base past what we already have.

We have some clients that we work with every month because we have a contract with them, and we have some clients that kind of come and go. On a monthly basis, we probably work with about 25 to 30 clients and then as far as people who need a hard drive replaced or something like that, it adds about 10 to 15 extra clients a month.

IM: You and Brian own the business together. What are some of the pros and cons of being a couple and working together?

CG: There's a lot of pros. It's really good because you are both fully committed. We're normally on the same page; we're always on the same team. We're both here for Cyber One Solutions. It kind of helps that this is how we pay our bills too.

We're very actively involved and dedicated to it. Some of the cons could be that work never quits. Once you get home, what are you going to talk about? Well, we've been working together all day so we're going to talk about work.

I suspect that other couples talk about their different jobs, while we talk about things we worked on at the same company. It is a different dynamic. My parents actually own a company together and work together too, so it's not abnormal for me, I guess.

IM: As members of the Greater Houston LGBTQ Chamber of Commerce, you’re connected with a wide variety of entrepreneurs in the LGBTQ community. Why is having that support system so important?

CG: We're members of the LGBT Houston chamber, and we're also recently, as of March or April, we got our National LGBT Chamber certification. The Houston LGBT Chamber is one of our favorites. It's just a place where we feel like everybody is actually there for each other. They are there to meet new businesses and talk to everybody. It's super friendly, and it's a place where you can just be yourself. It's awesome. I love going to all of their events.

IM: What does pride month mean to you?

CG: Pride month to me is all about celebration, awareness, and remembrance. At Pride, everybody is there and we are all celebrating the fact that we are who we are, and we're all celebrating each other. Awareness kind of goes with celebration.

We start to see corporate logos change color. For example, I took a photo of the HP float at Pride because we are HP partners here at Cyber One, and I do a lot with HP computers. It was cool to see them have a float in the parade. A couple of our vendors that we use, their logos turned rainbow. It's just been really cool.

I would say that remembrance because at pride, they give you a second to stop and look back and see how far this community has come. We've had the Pulse nightclub shooting…we've had Stonewall, which was a theme of the Pride parade this year. It's just all of that wrapped together.

------

Portions of this interview have been edited.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings